Increased levels of circulating and tissue mRNAs of Oct-4, Sox-2, Bmi-1 and Nanog is ESCC patients: Potential tool for minimally invasive cancer diagnosis

Biomarker Insights

Volumn 7, Issue , 2012, Pages 27-37

  Bahl, Kriti ^a   Saraya, Anoop ^b   Sharma, Rinu ^a  

^a GURU GOBIND SINGH INDRAPRASTHA UNIVERSITY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bmi 1; Nanog; Oct3 4; Pluripotent; Sox 2

Indexed keywords

BMI1 PROTEIN; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ESOPHAGUS BIOPSY; ESOPHAGUS CANCER; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; MALE; MINIMALLY INVASIVE PROCEDURE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; TISSUE LEVEL;

EID: 84859520606     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/BMI.S8452     Document Type: Article

References (52)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23): 2241-52. Review.
2. Schöler HR. Octamania: the POU factors in murine development. Trends Genet. 1991;7:323-9.
3. Pesce M, Scholer, HR. Oct-4: gatekeeper in the beginnings of mammalian development. Stem Cells. 2001;19:271-8.
4. Scholer HR, Ruppert S, Suzuki N, Chowdhury K, Gruss P. New type of POU domain in germ line-specific protein Oct-4. Nature. 1990;344(6265): 435-9.
5. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis. 2005;26(2):495-502.
6. Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol. 2000;227(2):239-55.
7. Kamachi Y, Uchikawa M, Kondoh H. Pairing SOX off: with partners in the regulation of embryonic development. Trends Genet. 2000;16(4):182-7. Review.
8. Wenger M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res. 1999;27:1409-20.
9. Dong C, Wilhelm D, Koopman P. Sox genes and cancer. Cytogenet Genome Res. 2004;105(2-4):442-7.
10. Chambers I, Colby D, Robertson M, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 2003;113(5):643-55.
11. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5): 861-72.
12. Alkema MJ, Wiegant J, Raap AK, Berns A, van Lohuizen M. Characterization and chromosomal localization of the human proto-oncogene BMI-1. Hum Mol Genet. 2(10):1597-603.
13. Itahana K, Zou Y, Itahana Y, et al. Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol. 2003;23(1):389-401.
14. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, et al. Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol. 2007;20(4):474-81.
15. Kim JH, Yoon SY, Kim CN, et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/ p14 ARF proteins. Cancer Lett. 2004;203(2):217-4.
16. Vonlanthen S, Heighway J, Altermatt HJ, et al. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4 A-ARF locus expression. Br J Cancer. 2001;84(10):1372-6.
17. Guo WJ, Zeng MS, Yadav A, et al. Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res. 2007;67(11):5083-9.
18. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a sub-population of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007;104(3):973-8.
19. Liu JH, Song LB, Zhang X, et al. Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol. 2008;97(3):267-72.
20. He XT, Cao XF, Ji L, et al. Association between Bmi1 and clinicopathological status of esophageal squamous cell carcinoma. World J Gastroenterol. 2009;15(19):2389-94.
21. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst. 2006;9:1755-7.
22. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3: 730-7.
23. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464): 645-8.
24. Hemmati HD, Nakano I, Lazareff JA, et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003;100(25): 15178-83.
25. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821-8.
26. Alvi AJ, Clayton H, Joshi C, et al. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res. 2003;5(1): R1-8.
27. Welm BE, Tepera SB, Venezia T, Graubert TA, Rosen JM, Goodell MA. Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev Biol. 2002;245(1):42-56.
28. Huang D, Gao Q, Guo L, et al. Isolation and identification of cancer stemlike cells in esophageal carcinoma cell lines. Stem Cells Dev. 2009;18(3): 465-73.
29. Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol. 1993; 119:441-9.
30. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;1448(7151):313-7.
31. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917-20.
32. Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451(7175):141-6.
33. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397(6715):164-8.
34. Jacobs JJ, Scheijen B, Voncken JW, et al. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 1999;13(20):2678-90.
35. Shilatifard A. Chromatin modifications by methylation and ubiquitination: Implications in the regulation of gene expression. Ann Rev Biochem. 2006; 75:243-69.
36. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006;6:846-56.
37. Chang CC, Sun W, Cruz A, Saitoh M, Tai MH, Trosko JE. A human breast epithelial cell type with stem cell characteristics as target cells for carcinogenesis. Radiat Res. 2001;155:201-7.
38. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK, Trosko JE. Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. Carcinogenesis. 2005;26(2):495-502.
39. Jin T, Branch DR, Zhang X, Qi S, Youngson B, Goss PE. Examination of POU homeobox gene expression in human breast cancer cells. Int J Cancer. 1999;81(1):104-12.
40. Xu K, Zhu Z, Zeng F. Expression and significance of Oct4 in bladder cancer. J Huazhong Univ Sci Technology Med Sci. 2007;27(6):675-7.
41. Gidekel S, Pizov G, Bergman Y, Pikarsky E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell. 2003;4(5):361-70.
42. Wang Q, He W, Lu C, et al. Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res. 2009;(4):1233-41.
43. Saigusa S, Tanaka K, Toiyama Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009;16(12):3488-98.
44. Hussenet T, Dali S, Exinger J, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 2010;5(1):e8960.
45. Lu Y, Futtner C, Rock JR, et al. Evidence that SOX2 overexpression is oncogenic in the lung. PLoS One. 2010;5(6):e11022.
46. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineagesurvival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41(11):1238-42.
47. Güre AO, Stockert E, Scanlan MJ, et al. Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A. 2000;97(8):4198-203.
48. Comtesse N, Zippel A, Walle S, et al. Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci U S A. 2005;102(27):9601-6.
49. Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, Tsutani Y. Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor Sox2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas. 2006;32: 164-70.
50. Li XL, Eishi Y, Bai YQ, et al. Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol. 2004;24(2): 257-63.
51. Sattler HP, Lensch R, Rohde V, et al. Novel amplification unit at chromosome 3q25-q27 in human prostate cancer. Prostate. 2000;45(3):207-15.
52. Chiou SH, Yu CC, Huang CY, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res. 2008;14(13):4085-95.